함께 비교하는 진짜 ADC · Antibody · CGT 데이터

AntibodystaleDaping Hospital and the Researc…Phase 2

PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor))

Colon Adenocarcinoma · Colon Adenocarcinoma

#ColonAdenocarcinoma#Antibody#Phase2#항체#면역항체+2

AntibodystaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#항체#면역항체+2

AntibodystaleMerckPhase 1

pembrolizumab (Keytruda, Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis)

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#항체#면역항체+2

CGTBiologicstaleAffiliated Hospital of Jiangnan…Phase 1

IFN-γ and CIK cells, Tcm cells or CAR T cells (IFN-γ and CIK cells, Tcm cells or CAR T cells)

Pleural Effusion, Malignant · Pleural Effusion, Malignant

#PleuralEffusionMalignant#CGT#Phase1#세포유전치료#CAR-T+4

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+3

atezolizumab (Tecentriq, PXS-5505 and Atezolizumab and Bevacizumab)

Hepatocellular Carcinoma; Cancer of Liver · Hepatocellular Carcinoma

임상시험 1상태 DISCONTINUED

AntibodystaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 DISCONTINUED

AntibodystaleRochePreclinical

atezolizumab (Tecentriq, Carboplatin/Cisplatin -Etoposide - Atezolizumab)

Small Cell Lung Cancer; Large Cell Neuroendocrine (NE) Tumors · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Preclinical#항체#면역항체+3

#HepatocellularCarcinoma#Antibody#Phase2#항체#면역항체+2

AntibodyRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

AntibodystaleBristol Myers SquibbPhase 2

pembrolizumab (Keytruda, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab)

Metastatic Cancer; Melanoma Cancer · Metastatic Cancer

#MetastaticCancer#Antibody#Phase2#항체#면역항체+3

AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Selumetinib + ZEN-3694 ± Durvalumab)

MPNST; NF1 · MPNST

#MPNST#Antibody#Phase2#항체#면역항체+3

AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Docetaxel, Oxaliplatin, S-1 and Durvalumab)

Resectable Gastric or Gastroesophageal Junction Adenocarcinoma · Resectable Gastric or Gastroesophageal J

#ResectableGastricorGastroesophag#Antibody#Phase2#항체#면역항체+2

#HER2#Antibody#Phase2#항체#면역항체+4

trastuzumab (Herceptin, Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab)

HR Positive/HER2 Low Breast Cancer · HER2

AntibodystaleBristol Myers SquibbPhase 1

nivolumab (Opdivo, TJ033721, TJ033721 (givastomig) , nivolumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3

AntibodystaleAstraZenecaPhase 2

durvalumab (Imfinzi, Neoadjuvant chemotherapy+Durvalumab+Tremelimumab)

Ovarian Cancer Stage IIIC; Ovarian Cancer Stage IV · Ovarian Cancer Stage IIIC

#OvarianCancerStageIIIC#Antibody#Phase2#항체#면역항체+3

#BreastNeoplasm#Antibody#Phase2#항체#면역항체+2

trastuzumab (Herceptin, doxorubicin, cyclophosphamide, paclitaxel, trastuzumab)

Breast Neoplasm · Breast Neoplasm

CGTAAVBiologicstaleWeill Medical College of Cornel…Phase 1

AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies (AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies)

Batten Disease; Late-Infantile Neuronal Ceroid Lipofuscinosis · Batten Disease

#BattenDisease#CGT#Phase1#세포유전치료#CAR-T+3

AntibodystaleRochePhase 3

Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix (Experimental Treatment: one course Rituximab/HD-Methotrexate, two courses of MATRix)

Primary Central Nervous System Lymphoma · Primary Central Nervous System Lymphoma

#PrimaryCentralNervousSystemLymph#Antibody#Phase3#항체#면역항체+2

AntibodystaleJunshi BiosciencesPhase 2

Toripalimab+cetuximab (Toripalimab+cetuximab)

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma · Patients With Locally Recurrent Resectab

#PatientsWithLocallyRecurrentRese#Antibody#Phase2#항체#면역항체+2

AntibodystaleInstitut für Klinische Krebsfor…Phase 2

Glofitamab as Consolidation therapy (Glofitamab as Consolidation therapy)

Relapsed /Refractory DLBCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4

CGTBiologicstaleMedical College of WisconsinPhase 1

up to 9 x 108 cells per dose (FT836 CAR T cells, FT836 CAR T cells (up to 9 x 108 cells per dose))

Relapse Multiple Myeloma; Refractory Multiple Myeloma · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+4

AntibodystaleEli LillyPhase 2

Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel (Drug: Tislelizumab, Cetuximab, Cisplatin and Nab-paclitaxel)

Oral Squamous Cell Carcinoma (OSCC); Oropharyngeal Squamous Cell Carcinoma (SCC) · Oral Squamous Cell Carcinoma (OSCC)

#OralSquamousCellCarcinomaOSCC#Antibody#Phase2#항체#면역항체+3

AntibodystaleEli LillyPhase 2

toripalimab + cetuximab + platinum (three cycles, three cycles (toripalimab + cetuximab + platinum))

Locally Advanced Hypopharyngeal Carcinoma · Locally Advanced Hypopharyngeal Carcinom

#LocallyAdvancedHypopharyngealCar#Antibody#Phase2#항체#면역항체+2

AntibodystaleEli LillyPhase 2

Irinotecan Liposomes (II, Irinotecan Liposomes, Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl)

Colorectal Cancer Metastatic · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#항체#면역항체+2

#MetastaticColorectalCancerCRC#Antibody#Phase2#항체#면역항체+2

TAS-102+bevacizumab+local treatment (TAS-102+bevacizumab+local treatment)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)